The collaboration will draw on the companies’ respective expertise in an attempt to improve the toxicology service Genstruct can offer to its clients.
Keith Elliston, president and CEO of Genstruct, said: "We are excited by the potential of combining the skill sets of the two companies. In Genstruct's work with pharmaceutical clients, we have characterised complex and poorly understood mechanisms of toxicity such as idiosyncratic drug-induced liver injury and hemangiosarcoma.
“Partnering with a highly regarded data provider like Gene Logic, we can now offer pharmaceutical clients of both companies tremendous additional value in toxicity evaluation."
Clients using Gene Logic’s gene expression technology in preclinical and clinical research have generated extensive toxicology databases, which will be used by Genstruct in the collaboration.
By applying its Causal Network Modeling platform to these datasets Genstruct believes it can fully evaluate a compound’s toxicity, even extrapolating the effects in humans from data in animals.
The companies will also participate in co-marketing initiatives and other projects are in the pipeline, including work to further personalised oncology medicines.
To achieve this Gene Logic will generate gene expression data from patient tumours, which Genstruct will then analyse using its systems biology platform. By doing this Genstruct hopes to gain a comprehensive understanding of an individual patient’s disease.
These combinations of niche expertise will, according to Anuradha Acharya, CEO of Gene Logic, “create integrated solutions for our customers”, which will help the service providers differentiate themselves in a changing, challenging environment.